Immunoglobulin g lymphocytotoxic antibodies in clinical liver transplantation: Studies toward further defining their significance
Open Access
- 1 May 1995
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 21 (5) , 1345-1352
- https://doi.org/10.1002/hep.1840210519
Abstract
Twenty-two consecutive liver allograft recipients, who tested positive for immunoglobulin G (IgG) lympho-cytotoxicity were subjected to pretransplantion and posttransplantation immunologic monitoring of antidonor IgG lymphocytotoxic antibody titers, total hemolytic complement activity (CH100), circulating immune complexes (CIC), and platelet counts in an effort to improve our understanding of the preformed antibody state in clinical hepatic transplantation. Ten contemporaneous liver transplant recipients whose crossmatch results were negative and who experienced severe hepatocellular damage early after transplantation were included as controls. Crossmatch test results were negative 1 day after transplantation and during the 1 month follow-up remained negative in 14 of 22 (64%) sensitized recipients, most of whom had relatively low (≦ 1:16) antidonor IgG antibody titers before transplantation. After transplantation, this group and the control group experienced no thrombocytopenia, no increase of CIC, and a gradual increase in CH100 activity that reached normal levels within 1 week. A strong negative correlation between prothrombin time (PT) and CH100 activity in these groups of patients suggested that changes in CH100 activity (P < 0.0005) were tightly linked to liver synthetic function. In contrast, the crossmatch test results remained positive after transplantation in 8 of 22 (36%) sensitized recipients, all of whom had relatively high (> 1:32 to 1024) pretransplantation titers of antidonor IgG antibodies. After transplantation these patients developed a syndrome that was characterized by decreased CH100 activity and increased CIC compared with pretransplantation levels and refractory thrombocytopenia that was associated with a 50% allograft failure rate because of biopsy-proven humoral and acute (cellular) rejection. Moreover, the lack of a strong negative correlation between PT and CH100 activity (P = 0.1) in this group of patients suggested that the hypocomplementemia was not tightly linked to liver synthetic function. Before transplantation, determination of anti—donor antibody class (IgG) and titer alone showed a strong negative predictive value (100%) but less than optimal positive predictive value (67%) for identifying patients who experienced the posttransplantation syndrome described above. Therefore, evaluation of platelet counts, CH100 activity, CIC, persistence of anti-donor antibodies and results of a liver biopsy performed after transplantation assisted in identifying sensitized liver allograft recipients who suffered the adverse consequences of the preformed antibody state.Keywords
This publication has 49 references indexed in Scilit:
- Relevance of a positive crossmatch in liver transplantationTransplant International, 1991
- Relevance of a positive crossmatch in liver transplantationTransplant International, 1991
- PLATELET CROSSMATCHING FOR KIDNEY TRANSPLANTS BY FLOW CYTOMETRYTransplantation, 1989
- RELATIONSHIP BETWEEN THE LIVER AND LYMPHOCYTOTOXIC ALLOANTIBODIES IN INBRED RATSTransplantation, 1988
- Prolongation of Pig-to-Dog Renal Xenograft Survival by Modification of the Inflammatory Mediator ResponseAnnals of Surgery, 1987
- Interactions between liver allografts and lymphocytotoxic alloantibodies in inbred ratsHepatology, 1986
- DELAYED REJECTION OF HEART ALLOGRAFTS IN HYPERSENSITIZED RATS BY EXTRACORPOREAL DONOR-SPECIFIC LIVER HEMOPERFUSIONTransplantation, 1986
- PROSTAGLANDIN AS AN EFFECTIVE ANTIREJECTION THERAPY IN RAT RENAL ALLOGRAFT RECIPIENTSTransplantation, 1983
- Studies of hepatic synthesis in vivo of plasma proteins, including orosomucoid, transferrin, α-antitrypsin, C8, and factor BClinical Immunology and Immunopathology, 1980
- IMMUNOPATHOLOGICAL STUDIES OF ORTHOTOPIC HUMAN LIVER ALLOGRAFTSThe Lancet, 1972